The development of mAb formulations poses challenges at the manufacturing, stability, analytical, and administration levels.
Nilanjana Das, PhD
Advertisement
Nilanjana Das, PhD, is a senior research investigator at Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08903, US, nila.das@bms.com.
Articles by Nilanjana Das, PhD
Advertisement
Latest Updated Articles
Commercializing High-Concentration mAbsPublished: November 1st 2016 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
